Montelukast Für Kinder Im Alter Von 2 Bis 5 Jahren Eurogenerics (Montelukast)

Montelukast works by selectively blocking cysteinyl leukotriene (CysLT1) receptors in the respiratory tract. This inhibition prevents leukotriene‑mediated bronchoconstriction, mucus production, vascular leakage and inflammatory cell recruitment, leading to improved airway patency and reduced allergic inflammation.

The appropriate dose for a child aged 2‑5 years is determined by the prescribing clinician based on the child’s weight, severity of disease and current clinical guidelines. The prescriber will select the specific tablet strength and dosing frequency that best matches the individual patient’s needs.

Safety data for Montelukast in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast and inhaled corticosteroids act via different mechanisms; montelukast blocks leukotriene receptors, while inhaled corticosteroids reduce broad airway inflammation. Montelukast is often used as an add‑on therapy or for patients who cannot tolerate steroids, but it is not a direct substitute for the anti‑inflammatory potency of inhaled corticosteroids.

Montelukast tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Montelukast is taken orally, usually once daily in the evening, with or without food. The tablet is swallowed whole; it is not intended to be chewed, crushed or dissolved unless a specific formulation for that purpose is prescribed.

Serious risks include allergic reactions such as rash, angioedema or anaphylaxis, neuropsychiatric events like agitation, depression or suicidal thoughts, liver enzyme elevations indicating possible hepatic injury, and rare severe skin reactions such as Stevens‑Johnson syndrome. Any of these symptoms should prompt immediate medical evaluation.

Montelukast should not be used by individuals with a known hypersensitivity to the drug or any of its excipients. It is also contraindicated in children outside the approved age range (under 2 years or over 5 years for this specific pediatric formulation) unless directed by a healthcare professional.